Special Interest Satellite Symposia
Click on the sections below to learn more about the Special Interest Satellite Symposia. Please note the information might be subject to change.
Live November 16-19, 2021
Special Interest Satellite Symposium 01: Human Papilloma Virus latency: virological, immunological and clinical aspects:
10:30 AM – 12:00 PM EST (GMT-5)
Moderator:
P. Gravitt
Presentations:
- Molecular and virological aspects of HPV latency
J. Doorbar - Immunological aspects of HPV latency
M. Stanley - Clinical and epidemiological aspects of HPV latency
A. Hammer
Special Interest Satellite Symposium 02: Head and Neck Symposium on HPV: Research and education for HPV elimination:
12:30 AM – 14:00 PM EST (GMT-5)
Moderator:
S. Pai, C. Derkay
Presentations:
- Recurrent Respiratory Papillomatosis: Introduction of Topic and Speakers
C. Derkay - Recurrent Respiratory Papillomatosis: Evidence of the beneficial effects of HPV vaccination on reducing the incidence and prevalence
P. Campisi - Recurrent Respiratory Papillomatosis: Strategies for increasing uptake of the HPV vaccine in low and mid-resource countries to prevent RRP
S. Peer - Recurrent Respiratory Papillomatosis: Update on treatment of RRP – Surgical advances, adjuvant use and their timing, DNA vaccines
S. Pransky - Head and Neck Cancer: Introduction of the Topic and Speaker
S. Pai - Can uptake of the HPV vaccine among 27-45-year-old men prevent oropharyngeal cancers in the US?
R. Landy - Head and Neck Cancer: Immunotherapies, DNA vaccines, EGFR inhibitors and check-point inhibitors: state-of-the-art treatments of HPV-associated head and neck cancers
C. Allen - Head and Neck Cancer: What is different about HPV-associated head and neck cancers?: Diagnosis, Prevention, Education and Prognosis with de-intensified therapies
B. Haughey - Question and Answer session
All Speakers
Special Interest Satellite Symposium 03: Eliminating Cervical Cancer in Canada – from Action Plan to Action:
11:30 AM – 12:30 PM EST (GMT-5)
Presentations:
- The Action Plan for the elimination of cervical cancer in Canada
M. Halligan - Why eliminating cervical cancer matters – lived experience
C. Howard - Reaching 90% HPV immunization rate in Canada
C. Neudorf - Transitioning to HPV primary screening in Canada
G. Ogilvie - Improving access to appropriate follow-up in Canada
J. Bentley - Facilitated discussion on elimination of cervical cancer in Canada
M. Halligan, C. Howard, C. Neudorf, G. Ogilvie, J. Bentley
Special Interest Satellite Symposium 04: Single-dose HPV vaccination: a review of current evidence and future research directions:
18:15 – 19:45 PM EST (GMT-5)
Moderator:
A. Kreimer
- Evidence review on single-dose HPV vaccination from clinical trials
D. Watson-Jones - Observational studies of HPV vaccine effectiveness by number of doses
L. Markowitz - Global impact of single-dose HPV vaccination in modelling studies
K. Prem - Ongoing trials that directly evaluate single-dose HPV vaccine protection
A. Kreimer - Discussion
All Speakers
Presentations:
Special Interest Satellite Symposium 05: HPV-tests in cervical cancer screening: how will offering a choice of tests improve patient experience and engagement?:
14:00 – 15:00 EST (GMT-5)
Presentations:
- A Conjoint Analysis of Preferred Characteristics of Self-Sampling for Human Papillomavirus (HPV) Among Low-Income Women
E. Biederman - Cervical screening: As you like it
A. Lim - Home self-sampling for HPV testing: Are we there yet?
P. Madhivanan - The power of women’s autonomy in decision-making on HPV self-sampling in the Peruvian Amazon
V. Paz-Soldan
On Demand from Monday, November 15, 2021
These SISS on demand sessions have dedicated chat channels in the IPVC Chat Forum for lively discussions on these topics.
- SISS06: Policy & Communication
- SISS07: Biomarker Sources
- SISS08: COVID-19 & Cancer
- SISS09: Standard of Care
- SISS10: Automated Evaluation
- SISS11: Prevention for Indigenous
- SISS12: Anal Cancer
- SISS13: Monitoring Progress
- SISS14: Key Issues in Europe
- SISS15: Prevention for Pacific Islanders
- SSIS16: HPV Insights: Men
- SISS17: Conquering Cancer Feature
Special Interest Satellite Symposium 06: Thinking through the policies: the importance of good communication in HPV testing and vaccination:
On Demand
Moderator:
G. Zimet
- Communicating about cervical cancer screening results in the U.S
K. Head - The fall-out of bad communication strategies
R. Dodd - Using behavioural science to develop information about policy changes in screening
L. Marlow - Responding to an HPV vaccine confidence crisis- experience from Ireland
L. Jessop
Presentations:
Special Interest Satellite Symposium 07: First Void Urine as a Biomarker Source for Primary and Secondary HPV Related Cancer Prevention:
On Demand
Moderator:
A. Vorsters
- Introduction: Rationale of using first void urine as Biomarker Source of the female Genital Tract
A. Vorsters - Impact of HPV vaccination in resource limited settings
I. Baussano - Monitoring vaccine induced immune response using first void urine samples
L. Teblick - Cervical Cancer screening: Clinical Evaluation of hr.HPV assays using first void urine samples
S. Van Keer - Self-sampling for Cervical Screening with Urine or Vaginal Samples
J. Cuzick
Presentations:
Special Interest Satellite Symposium 07: First Void Urine as a Biomarker Source for Primary and Secondary HPV Related Cancer Prevention:
On Demand
Presentations:
- Welcome
E. Burger - Introduction to the CCGMC: scope, aims, work to date, challenges in collating and using registry data
J. O’Mahony - Real-world responses to pandemic-related cervical cancer screening disruptions
M. Elfström - Cervical screening and the COVID-19 pandemic: the experience of Ireland’s National Screening Service
C. Mohan - COVID-19 impact in high-income countries – insights and CCGMC work to date
M. Smith - COVID-19 impact on reaching the elimination targets in LMICs – insights and work to date
K. Simms - Panel discussion: Lessons learnt, addressing disparities, applications of self-sampling
Special Interest Satellite Symposium 09: Elevating the Standard of Care: A Novel Integrated Approach to the Control of Cervical Cancer and Female Genital Schistosomiasis:
On Demand
Moderator:
M. Steben
- Chair Introduction
M. Steben - Overview of Female Genital Schistosomiasis and opportunities for prevention
E. Kjetland - Cervical cancer screening: an opportunity for impact on FGS (ID 1067)
Presenter
M. Schiffman - Molecular approaches for screening FGS and cervical cancer
A. Bustinduy - An integrated approach to cervical cancer and FGS disease control
Z. Rosberger
Presentations:
Special Interest Satellite Symposium 10: Development of an Automated Visual Evaluation for Cervical Cancer Screening:
On Demand
Moderator:
S. De Sanjose & M. Schiffman
- Introduction to the Symposia: Scope-Moonshot NCI effort on AVE in cervical cancer screening in LMIC
M. Schiffman - Key elements of image quality and their impact in AVE performance. Hardware
D. Levitz - Main steps in AVE creation: From data sources to algorithms
B. Befano - Systematic approach to AVE evaluation
A. Lemay - Statistical approaches: AVE score to risk score or how to turn the score into a clinical test
D. Egemen - Strategy to evaluate treatability. How AVE can assist patient management
J. Jeronimo - Cautionary aspects on the AI application in the clinical settings
K. Desai - Next steps: Field evaluation and expected outcomes and closing remarks
S. De Sanjose
Presentations:
Special Interest Satellite Symposium 11: HPV disease prevention: realities for Indigenous peoples in a COVID19 environment:
On Demand
Moderator:
L. Whop & B. Lawton
- Introduction by the chairs: the Indigenous HPV Alliance
B. Lawton & L. Whop - Yarning about HPV and COVID-19 vaccination
T. Butler - Managing screening in a COVID19 environment for Māori
S. Te Whaiti - HPV self-testing in Samoa
A. Ekeroma & F. Amosa-Lei Sam - Pandemic-proof cancer screening: Using HPV self-screening to put cervix health into the hands of Métis communities in Northern British Columbia
K. Pollard
Presentations:
Special Interest Satellite Symposium 12: Anal cancer and precancerous lesions: what´s new?:
On Demand
Moderator:
A. Grulich
- Anal cancer risk scale
G. Clifford - Transplant recipients
A. Albuquerque - Women with lower genital neoplasia tract neoplasia
M. Nathan
Presentations:
Special Interest Satellite Symposium 13: A global standard for monitoring progress towards elimination: fidelity, the cancer continuum, and ensuring sustainable impact:
On Demand
Moderator:
A. Rositch
- Screening coverage, equity, and indicators
S. Kumar - Role of policy and working with ministry/national level stakeholders to ensure
S. Kapambwe
Presentations:
Special Interest Satellite Symposium 14: Key Issues in HPV Cancer Elimination In Europe: Challenges and opportunities:
On Demand
Presentations:
- The HPV Action Network’s priorities and plans
D. Kelly & R. Medeiros - Europe’s Beating Cancer Plan – HPV commitments and implementation
R. Price - Engaging young people in HPV prevention and advocacy
J. Crumière - Tackling vaccine hesitancy: harnessing the power of people’s stories to influence uptake
J. Daly - Advocating for change: a single-country case study
P. Drakos - Cervical cancer screening in the COVID era: strategies for increasing coverage
M. Gultekin
Special Interest Satellite Symposium 15: Caught between a Rock and a Hardplace: The US Pacific Island and cervical cancer preventions:
On Demand
Moderator:
M. Saraiya
- Caught between a Rock and a Hard Place
N. Palafox - Yap and FSM
M. Reichhardt - Background of CDC work with Pacific Islands
J. Qin - Behavioral interventions related to recruitment and education
I. Scarinci - Screening and Management Algorithms for Guam and Yap
R. Lu - Preliminary modelling results on potential benefits of HPV testing if high screening coverage and treatment compliance achieved in Guam and FSM/Yap
D. Nguyen
Presentations:
Special Interest Satellite Symposium 16: Anogenital and oral HPV infection in men: novel insights from vaccine and modeling studies:
On Demand
Presentations:
- Introduction
J. Palefsky - Natural history of anogenital HPV infection and HPV-associated disease: data from the V501-020 study: Baseline serology/infection to nine anogenital HPV types
S. Goldstone - Natural history of anogenital HPV infection and HPV-associated disease: data from the V501-020 study: Incidence of anogenital infection/disease in young men
A. Giuliano - Natural history of anogenital HPV infection and HPV-associated disease: data from the V501-020 study: Progression of anogenital HPV infection to disease
J. Palefsky - Oral HPV infection in men: Modeling natural history of oral HPV infection
R. Landy - Oral HPV infection in men: Projecting the impact of HPV vaccination on the incidence of oropharyngeal cancer in the 21st century in the U.S.
A. Deshmukh - Oral HPV infection in men: Design of BROADEN and PROGRESS natural history studies
L. Alemany - Safety and efficacy of HPV vaccination in men: Summary of 15 years of efficacy data from v501/v503 in men
Y. Tu - Safety and efficacy of HPV vaccination in men: Real-world evidence of vaccine effectiveness against oral HPV infection
L. Alemany - Safety and efficacy of HPV vaccination in men: Real-world evidence of vaccine effectiveness against oral HPV infection
L. Alemany - Closing
J. Palefsky
Special Interest Satellite Symposium 17: Conquering Cancer Feature Documentary Screening:
On Demand
Presentations:
- Short Movie – Conquering Cancer
- Short Movie – Living with HIV/AIDS and Cervical Cancer – Loyce’s Story
- Short Movie – Reducing Obstacles to Cervical Cancer Screening – Conquering Cancer
- Short Movie – Zambia Elimination Success Story
- Panel Discussion
K. Canfell, M. Saville AM, J. Torode, S. de Sanjose, N. Broutet, S. Kapambwe, L. Kabali